<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02437344</url>
  </required_header>
  <id_info>
    <org_study_id>#7057</org_study_id>
    <nct_id>NCT02437344</nct_id>
  </id_info>
  <brief_title>Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence</brief_title>
  <official_title>Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Opioid dependence is a substantial problem associated with significant morbidity and
      mortality. Extended-release naltrexone has been found effective at reducing opioid use and
      maintaining abstinence, but its use has been limited by the difficulties encountered with
      treatment initiation, which involves detoxification from opioids and oral naltrexone
      titration. Improving the likelihood of a successful transition to naltrexone is therefore an
      important public health goal.

      N-methyl-D-aspartate receptor (NMDA) antagonism has been found to alleviate the signs and
      symptoms of withdrawal from opioids, as well as to address adaptations associated with
      chronic opioid use, such as opioid-induced hyperalgesia (increased pain sensitivity). These
      benefits may persist for at least 72 hours after a single dose. NMDA antagonism may therefore
      facilitate a rapid transition to naltrexone by reducing discomfort, improving motivation, and
      ameliorating adaptations associated with drug dependence, such as craving and arousal.

      The purpose of this trial is to assess the feasibility of NMDA antagonist-assisted naltrexone
      initiation in opioid dependent individuals. After administration of extended-release
      naltrexone, participants will be followed for 4 weeks, and transitioned to appropriate care
      subsequently (oral naltrexone, extended-release naltrexone).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful Naltrexone Initiation</measure>
    <time_frame>2 weeks</time_frame>
    <description>The proportion of participants enrolled in the trial and receiving the infusion to receive XR-NTX</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Withdrawal: Subjective Opioid Withdrawal Scale Scores at Baseline and Administered Subsequently</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Opioid Dependence</condition>
  <arm_group>
    <arm_group_label>CI-581aa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CI-581aa will be administered 24 hours after last opioid use, and followed by naltrexone dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CI-581aa</intervention_name>
    <description>92 minute infusion of CI-581aa</description>
    <arm_group_label>CI-581aa</arm_group_label>
    <other_name>NMDA antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone titration and XR-NTX initiation</intervention_name>
    <description>participants will be provided a titration of naltrexone that culminates in the injection of XR-NTX</description>
    <arm_group_label>CI-581aa</arm_group_label>
    <other_name>naltrexone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Active opioid dependence, with at least one positive utox result; no history of opioid
             overdose; and not currently using methadone or buprenorphine

          2. Physically healthy

          3. No adverse reactions to study medications

          4. 21-60 years of age

          5. Capacity to consent and comply with study procedures

          6. Seeking treatment

        Exclusion Criteria:

          1. Meets DSM IV criteria for current major depression, bipolar disorder, schizophrenia,
             any psychotic illness, including substance-induced psychosis, and current
             substance-induced mood disorder with HAMD &gt; 12.

          2. Physiological dependence on another substance requiring medical management, such as
             alcohol or benzodiazepines, excluding caffeine, nicotine, and cannabis

          3. Pregnant or interested in becoming pregnant

          4. Delirium, Dementia, Amnesia, Cognitive Disorders, or dissociative disorders

          5. Current suicide risk or a history of suicide attempt within the past 2 years

          6. On psychotropic or other medication whose effect could be disrupted by participation
             in the study

          7. Recent history of significant violence (past 2 years).

          8. Heart disease as indicated by history, abnormal ECG, previous cardiac surgery.

          9. Unstable physical disorders which might make participation hazardous such as end-stage
             AIDS, hypertension (&gt;140/90), anemia, active hepatitis or other liver disease
             (transaminase levels &lt; 2 X the upper limit of normal will be considered acceptable),
             or untreated diabetes

         10. Previous history of CI-581 abuse, and/or a history of adverse reaction/experience wtih
             prior exposure to CI-581 or benzodiazepines

         11. BMI &gt; 35, or a history of unmanaged obstructive sleep apnea

         12. First degree relative with a psychotic disorder (bipolar disorder with psychotic
             features, schizophrenia, schizoaffective disorder, or psychosis NOS)

         13. History of opioid overdose over the past 2 years requiring medical intervention

         14. Currently using methadone or buprenorphine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elias Dakwar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYSPI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2015</study_first_submitted>
  <study_first_submitted_qc>May 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2015</study_first_posted>
  <results_first_submitted>August 7, 2017</results_first_submitted>
  <results_first_submitted_qc>August 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 6, 2017</results_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CI-581aa</title>
          <description>CI-581aa will be administered 24 hours after last opioid use, and followed by naltrexone dosing
CI-581aa: 92 minute infusion of CI-581aa
Naltrexone titration and XR-NTX initiation: participants will be provided a titration of naltrexone that culminates in the injection of XR-NTX</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CI-581aa</title>
          <description>CI-581aa will be administered 24 hours after last opioid use, and followed by naltrexone dosing
CI-581aa: 92 minute infusion of CI-581aa
Naltrexone titration and XR-NTX initiation: participants will be provided a titration of naltrexone that culminates in the injection of XR-NTX</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.8" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>baseline opioid use (morphine equivalents)</title>
          <units>morphine eq, in mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="297.7" spread="113.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Successful Naltrexone Initiation</title>
        <description>The proportion of participants enrolled in the trial and receiving the infusion to receive XR-NTX</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CI-581aa</title>
            <description>CI-581aa will be administered 24 hours after last opioid use, and followed by naltrexone dosing
CI-581aa: 92 minute infusion of CI-581aa
Naltrexone titration and XR-NTX initiation: participants will be provided a titration of naltrexone that culminates in the injection of XR-NTX</description>
          </group>
        </group_list>
        <measure>
          <title>Successful Naltrexone Initiation</title>
          <description>The proportion of participants enrolled in the trial and receiving the infusion to receive XR-NTX</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Withdrawal: Subjective Opioid Withdrawal Scale Scores at Baseline and Administered Subsequently</title>
        <time_frame>5 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 months, from treatment entry through the 1 month follow-up.</time_frame>
      <desc>It does not differ.</desc>
      <group_list>
        <group group_id="E1">
          <title>CI-581aa</title>
          <description>CI-581aa will be administered 24 hours after last opioid use, and followed by naltrexone dosing
CI-581aa: 92 minute infusion of CI-581aa
Naltrexone titration and XR-NTX initiation: participants will be provided a titration of naltrexone that culminates in the injection of XR-NTX</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Linda Sherman</name_or_title>
      <organization>NYSPI</organization>
      <phone>6467747158</phone>
      <email>lsherma@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

